JP2023521564A - コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法 - Google Patents

コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法 Download PDF

Info

Publication number
JP2023521564A
JP2023521564A JP2022556017A JP2022556017A JP2023521564A JP 2023521564 A JP2023521564 A JP 2023521564A JP 2022556017 A JP2022556017 A JP 2022556017A JP 2022556017 A JP2022556017 A JP 2022556017A JP 2023521564 A JP2023521564 A JP 2023521564A
Authority
JP
Japan
Prior art keywords
coronavirus
pharmaceutically acceptable
treating
acid
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521564A5 (https=
JPWO2021186053A5 (https=
Inventor
タツィ，ジャマル
エールリッヒ，ハルトムート
プーレッティ，フィリップ
サント，ジュリアン
シェラー，ディディエ
Original Assignee
アビバックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20305299.8A external-priority patent/EP3881844A1/en
Priority claimed from EP20305327.7A external-priority patent/EP3884946A1/en
Application filed by アビバックス filed Critical アビバックス
Publication of JP2023521564A publication Critical patent/JP2023521564A/ja
Publication of JP2023521564A5 publication Critical patent/JP2023521564A5/ja
Publication of JPWO2021186053A5 publication Critical patent/JPWO2021186053A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022556017A 2020-03-20 2021-03-19 コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法 Pending JP2023521564A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20305299.8A EP3881844A1 (en) 2020-03-20 2020-03-20 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305299.8 2020-03-20
EP20305327.7A EP3884946A1 (en) 2020-03-25 2020-03-25 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305327.7 2020-03-25
EP20305482 2020-05-12
EP20305482.0 2020-05-12
EP20306483.7 2020-12-03
EP20306483 2020-12-03
PCT/EP2021/057123 WO2021186053A1 (en) 2020-03-20 2021-03-19 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Publications (3)

Publication Number Publication Date
JP2023521564A true JP2023521564A (ja) 2023-05-25
JP2023521564A5 JP2023521564A5 (https=) 2024-03-29
JPWO2021186053A5 JPWO2021186053A5 (https=) 2024-03-29

Family

ID=74884979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556017A Pending JP2023521564A (ja) 2020-03-20 2021-03-19 コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法

Country Status (11)

Country Link
US (1) US20230142547A1 (https=)
EP (1) EP4121053A1 (https=)
JP (1) JP2023521564A (https=)
KR (1) KR20220152292A (https=)
CN (1) CN115605205A (https=)
AU (1) AU2021238792A1 (https=)
BR (1) BR112022018793A2 (https=)
CA (1) CA3172179A1 (https=)
IL (1) IL296522A (https=)
MX (1) MX2022011596A (https=)
WO (1) WO2021186053A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN118373771A (zh) * 2023-01-20 2024-07-23 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505909A (ja) * 2015-02-23 2018-03-01 アビバックス ウィルス感染の処置又は予防において使用する為のキノリン誘導体
JP2018507215A (ja) * 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体
JP2023519035A (ja) * 2020-04-05 2023-05-10 ファイザー・インク Ｃｏｖｉｄ－１９を処置するための化合物および方法
JP2023522811A (ja) * 2020-01-31 2023-06-01 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの共結晶及びその塩
JP2023532163A (ja) * 2020-01-31 2023-07-27 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの非晶質固体分散物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225363A1 (en) 2003-11-21 2007-09-27 The University Of Newcastle Research Associates Ltd. Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505909A (ja) * 2015-02-23 2018-03-01 アビバックス ウィルス感染の処置又は予防において使用する為のキノリン誘導体
JP2018507215A (ja) * 2015-02-23 2018-03-15 アビバックス ウィルス感染の処置及び予防において使用する為の新規なキノリン誘導体
JP2023522811A (ja) * 2020-01-31 2023-06-01 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの共結晶及びその塩
JP2023532163A (ja) * 2020-01-31 2023-07-27 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの非晶質固体分散物
JP2023519035A (ja) * 2020-04-05 2023-05-10 ファイザー・インク Ｃｏｖｉｄ－１９を処置するための化合物および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALLAWAY E. ET AL., NATURE, vol. 577, JPN6025011664, 30 January 2020 (2020-01-30), pages 605 - 607, ISSN: 0005692671 *
CAMPOS N. ET AL., RETROVIROLOGY, vol. 12:30, JPN6025011669, 2015, ISSN: 0005692673 *
CLINICALTRIALS.GOV ID NCT04393038: ""ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19", CLINICALTRIALS.GOV [ONLINE], JPN6025011670, 18 May 2020 (2020-05-18), ISSN: 0005557899 *
VAUTRIN A. ET AL., SCIENTIFIC REPORTS, vol. 9:792, JPN6025011667, 2019, ISSN: 0005692672 *

Also Published As

Publication number Publication date
EP4121053A1 (en) 2023-01-25
AU2021238792A1 (en) 2022-10-13
BR112022018793A2 (pt) 2022-11-29
WO2021186053A1 (en) 2021-09-23
CA3172179A1 (en) 2021-09-23
KR20220152292A (ko) 2022-11-15
MX2022011596A (es) 2022-10-18
CN115605205A (zh) 2023-01-13
US20230142547A1 (en) 2023-05-11
IL296522A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
KR102412581B1 (ko) miRNA-124 바이오마커
JP2009523410A (ja) 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
EP2825173B1 (en) Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
US20170226596A1 (en) Detection of viral infection
JP2023521564A (ja) コロナウイルス科ウイルス感染症を処置又は予防する為の化合物及びコロナウイルス科ウイルス感染症の発生を評価する方法及び使用方法
JP2010504332A (ja) アルツハイマー病の診断方法及び遺伝子マーカー
CN111886026A (zh) 用于治疗或预防高细胞因子血症和重度流感的方法和化合物
US20250255871A1 (en) Systems and methods for treating cancer
CA2978616A1 (en) Methods of treating inflammatory bowel disease with ifn-gamma therapy
Niu et al. Disrupting endogenous retroelements with a reverse transcriptase inhibitor alleviates DSS-induced colitis in mice
CN108165632B (zh) Linc01426在肝细胞癌诊断和治疗中的应用
EP3884946A1 (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
HK40077570A (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
Fu et al. Dynamic change of shanks gene mRNA expression and DNA methylation in epileptic rat model and human patients
WO2005112924A2 (en) Methods of treating cancer by inhibiting histone gene expression
CN114525342B (zh) Linc02806在肝细胞癌诊断和治疗中的应用
CN111635946B (zh) 一种诊治胶质瘤的分子生物标志物及其应用
EP3881844A1 (en) Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2023170187A1 (en) INHIBITION OF INTRACELLULAR PATHOGEN UPTAKE BY INHIBITORS OF THE IKK-α/NIK COMPLEX
US10517842B2 (en) Methods of modulating miRNA levels and compositions for use in the same
CN111363824A (zh) 一种用于肝癌诊断的lncRNA生物标志物及其应用
US8697681B2 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
JP7650467B2 (ja) 自己免疫疾患及び／又は炎症性疾患の判定方法、並びに炎症性疾患及び／又は自己免疫疾患の予防及び／又は治療剤
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
HK1218766B (zh) 作为生物标记物的mirna-124

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250924